Business Context and Reporting Period
This Form 8-K is a current report filed by Shuttle Pharmaceuticals Holdings, Inc. on July 24, 2025. The company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC under the symbol SHPH. The registrant is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The primary material change reported is the departure of senior management:
- Resignation: Peter Dritschilo resigned as President, Chief Operating Officer, and Secretary.
- Effective Date: July 24, 2025.
- Succession: Christopher Cooper is identified as the Interim Chief Executive Officer who signed the report.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, outlook, management commentary on strategy, specific risks, contingencies, or unusual items beyond the executive departure.
Investor Verification Checklist
- Verify the reason for Peter Dritschilo's resignation and whether it was voluntary or related to a disagreement.
- Confirm the duration of Christopher Cooper's interim role and the timeline for appointing a permanent CEO.
- Review subsequent filings for any impact of this leadership change on ongoing clinical trials or operational strategy.